Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate risk of cancer incidence and mortality associated with the use of REGRANEX (becaplermin) in patients with diabetes who are members of a U.S. Veterans Health Administration.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Collaborator: Bedford Research Corporation, Inc.
• Treatments: Becaplermin; Platelet-derived growth factor BB

Criteria

Inclusion Criteria:

• Patients with diabetic foot ulcers who are members of the U.S Department of Veterans Affairs Health Care System (VA)

Exclusion Criteria:

• History of cancer (including nonmelanoma skin cancer) prior to study entry